Oxford BioDynamics (LON:OBD) Releases Earnings Results

Oxford BioDynamics (LON:OBD) announced its quarterly earnings results on Tuesday. The biotechnology company reported GBX (0.10) earnings per share for the quarter, Digital Look Earnings reports. Oxford BioDynamics had a negative return on equity of 316.67% and a negative net margin of 1,018.54%.The business had revenue of GBX 69 million during the quarter.

Oxford BioDynamics Trading Down 31.3%

LON OBD traded down GBX 0.05 during trading hours on Tuesday, hitting GBX 0.10. 199,230,953 shares of the company were exchanged, compared to its average volume of 16,074,189. Oxford BioDynamics has a 52 week low of GBX 0.09 and a 52 week high of GBX 0.78. The company has a quick ratio of 2.80, a current ratio of 0.88 and a debt-to-equity ratio of 457.97. The stock has a 50-day moving average price of GBX 0.19 and a 200 day moving average price of GBX 0.23. The stock has a market cap of £4.42 million, a PE ratio of -0.13 and a beta of 0.42.

About Oxford BioDynamics

Oxford BioDynamics Plc is a global biotechnology company, advancing personalized healthcare by developing and commercializing precision medicine tests for life-changing diseases.

Its flagship product is EpiSwitch® CiRT (Checkpoint Inhibitor Response Test) for cancer, a predictive immune response profile for immuno-oncology (IO) checkpoint inhibitor treatments, launched in February 2022.

In March 2021, the Company launched its first commercial prognostic test, EpiSwitch® CST (Covid Severity Test) and the first commercially available microarray kit for high-resolution 3D genome profiling and biomarker discovery, EpiSwitch® Explorer Array Kit.